Chemo Free Frontline Regimen Improves Ph Positive ALL EFS

Company GIMEMA (Italian cooperative group) Event Type Phase 3 Publication (NEJM) Modality Targeted therapy plus bispecific T-cell engager (chemotherapy-free regimen) Asset Ponatinib plus blinatumomab (GIMEMA ALL2820) Target BCR::ABL1; CD19xCD3 Disease Area Philadelphia chromosome-positive acute lymphoblastic leukemia (adults) Summary A peer-reviewed randomized Phase 3 GIMEMA ALL2820…